Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Know Labs Inc. (KNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: KNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $40
1 Year Target Price $40
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -85.09% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 822.26M USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 1 | Beta 1.76 | 52 Weeks Range 0.33 - 13.02 | Updated Date 09/16/2025 |
52 Weeks Range 0.33 - 13.02 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -363.88% | Return on Equity (TTM) -1867.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 290225026 | Price to Sales(TTM) 15.57 |
Enterprise Value 290225026 | Price to Sales(TTM) 15.57 | ||
Enterprise Value to Revenue 17.32 | Enterprise Value to EBITDA -3.51 | Shares Outstanding 384233984 | Shares Floating 7190007 |
Shares Outstanding 384233984 | Shares Floating 7190007 | ||
Percent Insiders 3.78 | Percent Institutions 0.08 |
Upturn AI SWOT
Know Labs Inc.
Company Overview
History and Background
Know Labs, Inc., formerly known as Vivosonic, Inc., was founded to develop and commercialize bio-sensor technology. They are focused on non-invasive glucose monitoring solutions.
Core Business Areas
- Bio-Sensor Technology Development: Development and commercialization of Radio Frequency (RF) based bio-sensors for non-invasive glucose monitoring.
Leadership and Structure
The leadership team is headed by Ron Erickson (CEO) and Phil Bosshard (CFO). The company has a functional organizational structure focused on research and development, and operations for clinical trails and product release.
Top Products and Market Share
Key Offerings
- KnowU: KnowU is a non-invasive glucose monitor currently undergoing clinical trials. Market share data is unavailable as the product is not yet commercially available. Competitors include companies developing continuous glucose monitoring (CGM) systems like Dexcom (DXCM) and Abbott (ABT).
Market Dynamics
Industry Overview
The medical device industry, specifically glucose monitoring, is experiencing significant growth due to the rising prevalence of diabetes and technological advancements.
Positioning
Know Labs is positioned as a disruptor in the glucose monitoring market with its non-invasive technology. Their competitive advantage lies in potentially eliminating the need for finger pricks.
Total Addressable Market (TAM)
The global glucose monitoring market is projected to reach billions of dollars. Know Labs is positioned to capture a significant share if their technology proves successful and gains regulatory approval.
Upturn SWOT Analysis
Strengths
- Non-invasive technology
- Potential to disrupt the glucose monitoring market
- Focus on patient comfort
Weaknesses
- Technology is still under development
- Requires regulatory approval (FDA)
- Limited financial resources
Opportunities
- Growing prevalence of diabetes
- Increasing demand for non-invasive monitoring solutions
- Potential partnerships with healthcare providers
Threats
- Competition from established CGM manufacturers
- Technological challenges
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- DXCM
- ABT
- TNDM
- SENS
Competitive Landscape
Know Labs is at a disadvantage compared to established CGM manufacturers due to their pre-revenue status. Their potential advantage is a new form factor which is non-invasive measurement.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable as the company is in the development stage.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approval, and market adoption of KnowU. Analyst estimates are unavailable
Recent Initiatives: Recent initiatives include advancing clinical trials for KnowU, securing patents, and seeking strategic partnerships.
Summary
Know Labs is a development-stage company with promising non-invasive glucose monitoring technology. Its success hinges on positive clinical trial results, FDA approval, and effective market penetration. It faces stiff competition from established players and significant regulatory hurdles. Funding will be required to continue operations until revenue can be created from operations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings, Company Website, Industry Reports, Analyst Estimates
Disclaimers:
This analysis is based on available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Know Labs Inc.
Exchange NYSE MKT | Headquaters Seattle, WA, United States | ||
IPO Launch date 2022-09-16 | CEO - | ||
Sector Technology | Industry Scientific & Technical Instruments | Full time employees 6 | Website https://www.knowlabs.co |
Full time employees 6 | Website https://www.knowlabs.co | ||
Know Labs, Inc., together with its subsidiaries, focuses on the development and commercialization of proprietary sensor technology by radio and microwave spectroscopy in the United States. The company involved in the identifying and measuring any material or analyte using electromagnetic energy to detect, record, identify, and measure the signature of said materials or analytes. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in May 2018. Know Labs, Inc. was incorporated in 1998 and is based in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.